Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | YAP1 | P46937 | 4/20 | 0.52 |
| ▸ | TEAD4 | Q15561 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963919 | 0.73 | ALDH1A1 (0.59) | ALDH1A1HTTRAB9AYAP1TEAD4 | |
| SCHEMBL13396259 | 0.71 | SMN1; SMN2 (0.57) | ALDH1A1HTTRAB9AYAP1TEAD4 | |
| SCHEMBL25252107 | 0.71 | SMN1; SMN2 (0.57) | ALDH1A1HTTRAB9AYAP1TEAD4 | |
| SCHEMBL9824635 | 0.70 | ALDH1A1 (1.00) | ALDH1A1HTTRAB9ASMN1; SMN2CNR2 | |
| SCHEMBL20442973 | 0.69 | KMT2A (0.51) | ALDH1A1HTTRAB9AYAP1TEAD4 | |
| SCHEMBL20447205 | 0.69 | ALDH1A1 (0.54) | ALDH1A1HTTRAB9AYAP1TEAD4 | |
| SCHEMBL3963003 | 0.69 | ALDH1A1 (0.68) | ALDH1A1HTTRAB9AYAP1TEAD4 | |
| SCHEMBL3520738 | 0.69 | ESR1 (0.73) | ALDH1A1RAB9ASMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL22202976 | 0.69 | L3MBTL1 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL29023817 | 0.68 | EPOR (0.43) | ALDH1A1HTTRAB9AL3MBTL1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12275741-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-11952381-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3843842-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885HTT 2905/4885RAB9A 836/4885 |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885HTT 2905/4885RAB9A 836/4885 |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885HTT 2905/4885RAB9A 836/4885 |
| US-12275741-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885HTT 2905/4885RAB9A 836/4885 |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885HTT 2905/4885RAB9A 836/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885HTT 2905/4885RAB9A 836/4885 |
| US-11952381-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885HTT 2905/4885RAB9A 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.